Ascendis Pharma A/S (ASND)

Market Cap	7.71B
Revenue (ttm)	357.63M
Net Income (ttm)	-545.18M
Shares Out	56.61M
EPS (ttm)	-9.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	243,229
Open	134.28
Previous Close	133.98
Day's Range	133.01 - 137.58
52-Week Range	85.29 - 161.00
Beta	0.59
Analysts	Strong Buy
Price Target	186.33 (+36.74%)
Earnings Date	May 2, 2024

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 28, 2015
• Employees: 879
• Stock Exchange: NASDAQ
• Ticker Symbol: ASND

Financial Performance

In 2023, ASND's revenue was 266.72 million, an increase of 421.20% compared to the previous year's 51.17 million. Losses were -481.45 million, -17.45% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 9 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is $186.33, which is an increase of 36.74% from the latest price.

Price Target

$186.33

(36.74% upside)

Analyst Consensus: Strong Buy